Research, Collaboration and Licensing Agreements

3 Months Ended

Mar. 31, 2022

License Agreements Research Collaborations And Development Agreements [Abstract]

Research, Collaboration and Licensing Agreements

Revenue recognized from the Company’s strategic partnerships is summarized as follows:


	Three Months Ended March 31,
	2022		2021

Research support and other payments	$	1,916	$	644
	$	1,916	$	644

Since December 31, 2021, there have not been any material changes to the key terms of our collaboration and license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please refer to the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year-ended December 31, 2021.

At March 31, 2022, contract assets from research, collaboration and licensing agreements were nil (December 31, 2021: nil) and contract liabilities were $32,941 (December 31, 2021: $32,941). Contract liabilities include deferred revenue relating to an upfront payment received in 2018 under the licensing and collaboration agreement with BeiGene. During the three months ended March 31, 2022, the Company did not recognize any revenue from performance obligations satisfied in relation to the deferred revenue (three months ended March 31, 2021: nil). Amounts not expected to be recognized as revenue in the next twelve months from March 31, 2022 have been classified as long-term deferred revenue.